GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heron Therapeutics Inc (NAS:HRTX) » Definitions » E10

Heron Therapeutics (Heron Therapeutics) E10 : $-3.17 (As of Mar. 2024)


View and export this data going back to 1987. Start your Free Trial

What is Heron Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Heron Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.020. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-3.17 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -0.30% per year. During the past 5 years, the average E10 Growth Rate was 1.70% per year. During the past 10 years, the average E10 Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Heron Therapeutics was 64.20% per year. The lowest was -90.10% per year. And the median was 14.80% per year.

As of today (2024-05-22), Heron Therapeutics's current stock price is $3.515. Heron Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-3.17. Heron Therapeutics's Shiller PE Ratio of today is .


Heron Therapeutics E10 Historical Data

The historical data trend for Heron Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heron Therapeutics E10 Chart

Heron Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.32 -3.18 -3.31 -3.46 -3.21

Heron Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.44 -3.38 -3.31 -3.21 -3.17

Competitive Comparison of Heron Therapeutics's E10

For the Biotechnology subindustry, Heron Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heron Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Heron Therapeutics's Shiller PE Ratio falls into.



Heron Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Heron Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.02/131.7762*131.7762
=-0.020

Current CPI (Mar. 2024) = 131.7762.

Heron Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.780 100.560 -1.022
201409 -0.660 100.428 -0.866
201412 -0.710 99.070 -0.944
201503 -0.700 99.621 -0.926
201506 -0.740 100.684 -0.969
201509 -0.630 100.392 -0.827
201512 -0.870 99.792 -1.149
201603 -0.920 100.470 -1.207
201606 -1.170 101.688 -1.516
201609 -1.240 101.861 -1.604
201612 -1.220 101.863 -1.578
201703 -1.000 102.862 -1.281
201706 -0.800 103.349 -1.020
201709 -0.770 104.136 -0.974
201712 -1.100 104.011 -1.394
201803 -0.810 105.290 -1.014
201806 -0.540 106.317 -0.669
201809 -0.490 106.507 -0.606
201812 -0.630 105.998 -0.783
201903 -0.800 107.251 -0.983
201906 -0.630 108.070 -0.768
201909 -0.420 108.329 -0.511
201912 -0.650 108.420 -0.790
202003 -0.570 108.902 -0.690
202006 -0.610 108.767 -0.739
202009 -0.640 109.815 -0.768
202012 -0.680 109.897 -0.815
202103 -0.580 111.754 -0.684
202106 -0.620 114.631 -0.713
202109 -0.510 115.734 -0.581
202112 -0.540 117.630 -0.605
202203 -0.630 121.301 -0.684
202206 -0.550 125.017 -0.580
202209 -0.380 125.227 -0.400
202212 -0.170 125.222 -0.179
202303 -0.270 127.348 -0.279
202306 -0.350 128.729 -0.358
202309 -0.170 129.860 -0.173
202312 -0.050 129.419 -0.051
202403 -0.020 131.776 -0.020

Add all the adjusted EPS together and divide 10 will get our e10.


Heron Therapeutics  (NAS:HRTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Heron Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Heron Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Heron Therapeutics (Heron Therapeutics) Business Description

Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Executives
William P Forbes officer: EVP, Chief Development Officer C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Adam Morgan other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Ira Duarte officer: EVP, Chief Financial Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Velan Capital Master Fund Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp other: See Footnote 2 1055B POWERS PLACE, ALPHARETTA GA 30009
David Efraim Rosen other: See Footnote 1 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Rubric Capital Management Lp other: See Footnote 1 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Balaji Venkataraman other: See Footnote 2 FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076
Kimberly Manhard director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Waage Christian director RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121

Heron Therapeutics (Heron Therapeutics) Headlines

From GuruFocus